Loading clinical trials...
Loading clinical trials...
Chemotherapy resistance is the greatest contributor to mortality in advanced cancers and severe challenges remain in finding effective treatment modalities to cancer patients with metastasized and rel...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Turku University Hospital
Collaborators
NCT05329532 · Triple Negative Breast Cancer, Renal Cell Cancer, and more
NCT05080556 · Ovarian Cancer, Relapsed Ovarian Cancer, and more
NCT03586661 · Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, and more
NCT03907852 · Mesothelioma, Mesothelioma, Malignant, and more
NCT03462342 · High Grade Serous Carcinoma
Turku University Hospital
Turku
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions